Verseau Therapeutics, Inc.
https://www.verseautx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Verseau Therapeutics, Inc.
Venture Funding Deals: Tenaya's $92m, Nuvation's $275m Lead October Rounds
Former Medivation CEO David Hung launched stealthy oncology start-up Nuvation with $275m in series A venture capital, while Tenaya's series B brought in $92m for small molecules as well as cell and gene therapies to treat cardiovascular diseases.
Finance Watch: BIO Says Proposed Foreign Investment Regulations Will Lower Investment In US Biotech
Private Company Edition: BIO comments suggest definitions of personal data expand the scope of foreign investments in biotech companies that must be reviewed by the Committee on Foreign Investment in the United States (CFIUS). Also, NeuroRx’s $95m deal leads recent private financings.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice